191 related articles for article (PubMed ID: 11606389)
1. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
[TBL] [Abstract][Full Text] [Related]
2. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
3. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
5. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.
Wang EJ; Johnson WW
Chemotherapy; 2003 Dec; 49(6):303-8. PubMed ID: 14671431
[TBL] [Abstract][Full Text] [Related]
6. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
Bruzek LM; Poynter JN; Kaufmann SH; Adjei AA
Mol Pharmacol; 2005 Aug; 68(2):477-86. PubMed ID: 15901852
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
Ramachandra M; Ambudkar SV; Gottesman MM; Pastan I; Hrycyna CA
Mol Biol Cell; 1996 Oct; 7(10):1485-98. PubMed ID: 8898356
[TBL] [Abstract][Full Text] [Related]
9. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
[TBL] [Abstract][Full Text] [Related]
10. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
[TBL] [Abstract][Full Text] [Related]
11. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
12. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
Barthomeuf C; Demeule M; Grassi J; Saidkhodjaev A; Beliveau R
Planta Med; 2006 Jun; 72(7):634-9. PubMed ID: 16739070
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol interaction with the daunorubicin binding site of P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Biochem Biophys Res Commun; 2000 Oct; 276(3):909-16. PubMed ID: 11027568
[TBL] [Abstract][Full Text] [Related]
14. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
O'Meara SJ; Kinsella BT
Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
Glass TL; Liu TJ; Yung WK
Neuro Oncol; 2000 Jul; 2(3):151-8. PubMed ID: 11302335
[TBL] [Abstract][Full Text] [Related]
16. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Feldkamp MM; Lau N; Roncari L; Guha A
Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
[TBL] [Abstract][Full Text] [Related]
17. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Adjei AA; Davis JN; Bruzek LM; Erlichman C; Kaufmann SH
Clin Cancer Res; 2001 May; 7(5):1438-45. PubMed ID: 11350915
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Nielsen LL; Shi B; Hajian G; Yaremko B; Lipari P; Ferrari E; Gurnani M; Malkowski M; Chen J; Bishop WR; Liu M
Cancer Res; 1999 Dec; 59(23):5896-901. PubMed ID: 10606231
[TBL] [Abstract][Full Text] [Related]
19. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
Chun KH; Lee HY; Hassan K; Khuri F; Hong WK; Lotan R
Cancer Res; 2003 Aug; 63(16):4796-800. PubMed ID: 12941797
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Robey RW; Shukla S; Finley EM; Oldham RK; Barnett D; Ambudkar SV; Fojo T; Bates SE
Biochem Pharmacol; 2008 Mar; 75(6):1302-12. PubMed ID: 18234154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]